 Silverback Therapeutics Inc NASDAQ: SBTX has presented interim data from a Phase 11b study of SBT6050 as a monotherapy and in combination with Merck Co Incs NYSE: MRK Keytruda pembrolizumab. Data were shared at the 2021 European Society for Medical Oncology Congress ESMO21. 